INNOVENTIS PHARMA
Board
1 director, no change since 2024Sole director
appointed by deed of 27-02-2024
term without a fixed end
earlier director, until 27-02-2024
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “de vennootschap in en buiten rechte rechtsgeldig verbonden door twee (2) gezamenlijk handelende bestuurders of door één (1) gedelegeerd bestuurder alleen handelend.”deed of 23-02-2018
Mandates through the years
1 name, the dashed line is todaySole director
BoardEarliermandate already running before its first mention
Mandates as a list
-
- Sole director, appointed by deed of 27-02-2024, still in office
- Director, until 27-02-2024
With Starter you also see 3 former office holders in the mandate history.
See the plans →
Control
Founders
,
This company
INNOVENTIS PHARMA
Equity €396,169
Profit €1,561 in 2025
Capital
- Capital
- €561,500
- Shares
- 22,825
- Contribution per share
- €24.60
- Equity per share
- €17.36 in 2025
- Source
- deed of 27-02-2024
Articles of association
deed of 27-02-2024 (in Dutch)- DurationMost companies exist for an unlimited period, until they are dissolved.
- Unlimited
- Board ruleThese rules set how the board is made up, meets and takes decisions.
- 1 director
- Kind of sharesThe articles set which classes of shares exist and what rights each class carries.
- Soort A Aandelen
- Transfer restrictionThis rule says whether shareholders may sell their shares freely or need approval first.
- EUR
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- “Organisatie en bijeenroeping De gewone algemene vergadering wordt jaarlijks gehouden op de laatste werkdag van mei…”
Founders
At incorporation
deed of 23-02-2018 ↗
- founder
- founder
Capital transactions
Capital over time
- 27-02-2024 Capital increase of €500,000 · to €561,500 · 20,325 new shares, 89% of the 22,825 shares after the increase · “inbreng (deel) schuldvordering”
- 23-02-2018 Incorporation · €61,500 · 2,500 shares